dacarbazine has been researched along with Lymphopenia in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B | 1 |
| Ligon, KL; Lim-Fat, MJ; Nassar, AH; Rahman, R; Shi, DD; Wen, PY; Youssef, GC | 1 |
| Garzio, K; Grossman, S; Holdhoff, M; McElroy, K; Ozer, B; Yankulina, O | 1 |
| Fukusumi, H; Goto, S; Handa, Y; Inazawa, Y; Kamigaki, T; Kanematsu, D; Kanemura, Y; Mori, K; Moriuchi, S; Nakajima, S; Nonaka, M; Okita, Y; Shofuda, T; Sumida, M; Takada, AI; Yamamoto, A; Yamasaki, M; Yoshioka, E | 1 |
| Archer, GE; Bigner, DD; Choi, BD; Cui, X; Flores, C; Herndon, JE; Johnson, LA; Mitchell, DA; Sampson, JH; Sanchez-Perez, LA; Schmittling, RJ; Snyder, D | 1 |
| Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ | 1 |
| Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD | 1 |
| Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS | 1 |
| Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S | 1 |
| Angelopoulou, MK; Boutsikas, G; Dimopoulou, MN; Dimou, M; Flevari, P; Gainaru, G; Kanellopoulos, A; Konstantopoulos, K; Koutsi, K; Kyrtsonis, MC; Meletis, J; Moschogiannis, M; Panayiotidis, P; Pangalis, GA; Papageorgiou, L; Petevi, K; Plata, E; Sachanas, S; Siakantaris, MP; Telonis, V; Tsaftaridis, P; Tsirkinidis, P; Variami, E; Vassilakopoulos, TP; Viniou, NA; Yiakoumis, X | 1 |
| Hop, WC; Jeurissen, FJ; Roon, K; Taphoorn, MJ; Vecht, CJ; Zwinkels, H | 1 |
| Hwu, WJ; Patel, SP; Trinh, VA | 1 |
| Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A | 1 |
| Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T | 1 |
| Aldape, KD; Archer, GE; Bigner, DD; Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gilbert, MR; Heimberger, AB; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sawaya, R; Schmittling, R; Shi, W; Vredenburgh, JJ | 1 |
| Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ | 1 |
| Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P | 1 |
| Gajewski, TF | 1 |
| Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD | 1 |
| Weller, M; Wick, W | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A | 1 |
| Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ | 1 |
| Wong, ET | 1 |
| Bertorelle, R; Biscuola, M; Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Ermani, M; Franceschi, E; Gioia, V; Tosoni, A | 1 |
| Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M | 1 |
| Armata, J; Balwierz, W; Borkowski, W; Depowska, T | 1 |
| Garaci, E; Izzo, F; Pierimarchi, P; Ranuzzi, M; Rasi, G; Sinibaldi-Vallebona, P; Terzoli, E; Tuthill, C | 1 |
3 review(s) available for dacarbazine and Lymphopenia
| Article | Year |
|---|---|
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Temozolomide | 2022 |
The safety of temozolomide in the treatment of malignancies.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Lymphopenia; Nausea; Neoplasms; Neutropenia; Radiotherapy; Temozolomide; Thrombocytopenia; Vomiting | 2009 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Immunologic Factors; Lymphopenia; Melanoma; Temozolomide; Treatment Outcome | 2010 |
6 trial(s) available for dacarbazine and Lymphopenia
| Article | Year |
|---|---|
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; DNA Methylation; ErbB Receptors; Female; Glioblastoma; Humans; Hypersensitivity, Delayed; Immunoenzyme Techniques; Lymphopenia; Male; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Survival Rate; T-Lymphocytes; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome; Vaccines, Subunit | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Daclizumab; Drug Evaluation, Preclinical; Glioblastoma; Humans; Immunoglobulin G; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Substrate Specificity; T-Lymphocytes, Regulatory; Temozolomide; Young Adult | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult | 2012 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; Disease Progression; DNA Methylation; Drug Administration Schedule; Female; Glioblastoma; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Safety; Survival Analysis; Thymalfasin; Thymosin; Treatment Outcome | 2000 |
18 other study(ies) available for dacarbazine and Lymphopenia
| Article | Year |
|---|---|
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Diseases; Lymphopenia; Methylhydrazines; Neutropenia; Temozolomide; Thrombocytopenia | 2022 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Dacarbazine; Female; Glioma; Humans; Immunotherapy, Adoptive; Lymphopenia; Male; Middle Aged; Prospective Studies; T-Lymphocyte Subsets; Temozolomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Immunotherapy; Interleukin-2; Lymphocyte Depletion; Lymphopenia; Mice; Mice, Transgenic; Temozolomide; Vaccines, Subunit | 2013 |
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; Cancer Vaccines; Dacarbazine; Glioblastoma; Humans; Lymphocyte Depletion; Lymphopenia; Temozolomide | 2013 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Odds Ratio; Radiotherapy Dosage; Regression Analysis; Sex Factors; Temozolomide; Young Adult | 2015 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Grading; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Craniospinal Irradiation; Dacarbazine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Glioblastoma; Humans; Lymphopenia; Male; Neoplasm Staging; Neuroectodermal Tumors, Primitive; Neutropenia; Prognosis; Survival Rate; Temozolomide; Thrombocytopenia; Young Adult | 2016 |
Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Monocytes; Retrospective Studies; Vinblastine; Young Adult | 2016 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Administration Schedule; Drug Monitoring; Glioma; Humans; Lymphopenia; Nausea; Netherlands; Neutropenia; Nurse Practitioners; Nurse's Role; Nursing Evaluation Research; Oncology Nursing; Prospective Studies; Statistics, Nonparametric; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Predictive Value of Tests; Radiotherapy, Adjuvant; Severity of Illness Index; Statistics, Nonparametric; Temozolomide | 2010 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; Melanoma; Opportunistic Infections; Temozolomide | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Melanoma; Middle Aged; Multivariate Analysis; Opportunistic Infections; Proportional Hazards Models; Retrospective Studies; Temozolomide | 2004 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2005 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Glioma; Humans; Infections; Lymphopenia; Male; Middle Aged; Temozolomide | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Feasibility Studies; Glioma; Humans; Lymphopenia; Temozolomide | 2006 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Herpes Zoster; Humans; Incidence; Lymphopenia; Male; Middle Aged; Neuroendocrine Tumors; Opportunistic Infections; Pneumonia, Pneumocystis; Temozolomide | 2007 |
Treatment of lymphocyte depletion Hodgkin's disease in children.
Topics: Adolescent; Bleomycin; Child; Child, Preschool; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Lymphopenia; Male; Neoplasm Staging; Vincristine | 1981 |